Cocrystal Pharma
Yahoo Finance • last month
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of Medicine... Full story
Yahoo Finance • 4 months ago
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon... Full story
Yahoo Finance • 6 months ago
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COC... Full story
Yahoo Finance • 6 months ago
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Opendoor Technologies Inc. 147,272,395 10.38 9.61 9.965 -0.555 Next Tech... Full story
Yahoo Finance • 6 months ago
Cocrystal Pharma announces up to $13 million registered direct offering
* Cocrystal Pharma (NASDAQ:COCP [https://seekingalpha.com/symbol/COCP]) has entered into definitive agreements for the purchase and sale of 2.76M shares of its common stock at a purchase price of $1.70 per share in a registered direct of... Full story
Yahoo Finance • 6 months ago
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COC... Full story
Yahoo Finance • 6 months ago
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s lead pan-viral proteas... Full story
Yahoo Finance • 7 months ago
Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Globa... Full story
Yahoo Finance • 7 months ago
Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: CO... Full story
Yahoo Finance • 9 months ago
H.C. Wainwright lowers Cocrystal Pharma stock price target on dilution
Investing.com - H.C. Wainwright lowered its price target on Cocrystal Pharma, Inc. (NASDAQ:COCP) to $6.00 from $7.00 while maintaining a Buy rating on Friday, citing anticipated equity dilution despite positive drug development progress. T... Full story
Yahoo Finance • last year
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now availa... Full story
Yahoo Finance • last year
Life Sciences Investor Forum Agenda Announced for March 13th
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Ca... Full story
Yahoo Finance • 2 years ago
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent broad-spectrum PB2 inhibitor CC-423... Full story
Yahoo Finance • 2 years ago
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive Officer, will present a Company overview a... Full story
Yahoo Finance • 2 years ago
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviralDosing expected to begin later this year in Phase 2a human challenge trial with oral CC-42344 for the... Full story
Yahoo Finance • 2 years ago
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces that President and co-CEO Sam Lee, PhD will discuss progress in developing the novel, broad-spectrum PB2 in... Full story
Yahoo Finance • 3 years ago
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and p... Full story
Yahoo Finance • 3 years ago
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel small molecule antiviral therapeutics, anno... Full story
Yahoo Finance • 3 years ago
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
On track to begin a Phase 2a trial in the second half of 2023with CC-42344 for the treatment ofpandemic and seasonal influenza ASelected the novel protease inhibitor CDI-988 as development lead inthe oral norovirus programCDI-988, the firs... Full story
Yahoo Finance • 3 years ago
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
BOTHELL, Wash., May 15, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three months ended March 31, 2023 and provides updates on its antiviral pipeline, upcomin... Full story
